European regulators have refused to back GlaxoSmithKline’s daily triple therapy Trelegy Ellipta for asthma, denying a label extension because there was no evidence to show a reduction of flare-ups. It ...
The list for the next round of medicines that will be subject to Medicare price negotiations isn’t in yet, but the Institute for Clinical and Economic Review (ICER) reckons a chronic obstructive ...
Tim Smith has 20+ years of experience in the financial services industry, both as a writer and as a trader. David Kindness is a Certified Public Accountant (CPA) and an expert in the fields of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback